Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 5, 2024
Discovery & Translation

Distillery spotlight: new Alzheimer’s mechanisms from academia

BioCentury’s survey of the 2023 translational literature highlights a cluster of neuron-targeting mechanisms for Alzheimer’s disease 
BioCentury | Jun 13, 2020
Translation in Brief

OSE identifies myeloid checkpoint target; plus a call from NCI for COVID-19 test proposals, Sinopharm vaccine data and more

BioCentury’s roundup of preclinical news
BioCentury | Jul 10, 2008
Distillery Therapeutics

This Week in Therapeutics

Items per page:
1 - 4 of 4